Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?

被引：40

作者：

Anestis, Aristomenis ^{[1
]}

Karamouzis, Michalis V. ^{[1
]}

Dalagiorgou, Georgia ^{[1
]}

Papavassiliou, Athanasios G. ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Dept Biol Chem, Mol Oncol Unit, GR-11527 Athens, Greece

来源：

CANCER TREATMENT REVIEWS | 2015年 / 41卷 / 06期

关键词：

Breast cancer; Androgen receptor; Estrogen receptor; Triple negative; MOLECULAR PORTRAITS; THERAPEUTIC TARGETS; SIGNALING PATHWAY; PIK3CA MUTATIONS; PHASE-II; TUMORS; EXPRESSION; BETA; GROWTH; IDENTIFICATION;

D O I：

10.1016/j.ctrv.2015.04.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype. The absence of expression and/or amplification of estrogen and progesterone receptor as well as ERBB-2 prevent the use of currently available endocrine options and/or ERBB-2-directed drugs and indicates chemotherapy as the main current therapy. TNBC represents approximately 15% of breast cancer cases with high index of heterogeneity. Here, we review the role of androgen receptor in breast carcinogenesis and its association with alterations in the expression pattern and functional roles of regulatory molecules and signal transduction pathways in TNBC. Additionally, based on the so far preclinical and clinical published data, we evaluate the perspectives for using and/or developing androgen receptor targeting strategies for specific TNBC subtypes. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：547 / 553

页数：7

共 67 条

[1]

[Anonymous], 2014, ADV AR TRIPL NEG BRE

[2] Sequence analysis of mutations and translocations across breast cancer subtypes [J].

Banerji, Shantanu ;

Cibulskis, Kristian ;

Rangel-Escareno, Claudia ;

Brown, Kristin K. ;

Carter, Scott L. ;

Frederick, Abbie M. ;

Lawrence, Michael S. ;

Sivachenko, Andrey Y. ;

Sougnez, Carrie ;

Zou, Lihua ;

Cortes, Maria L. ;

Fernandez-Lopez, Juan C. ;

Peng, Shouyong ;

Ardlie, Kristin G. ;

Auclair, Daniel ;

Bautista-Pina, Veronica ;

Duke, Fujiko ;

Francis, Joshua ;

Jung, Joonil ;

Maffuz-Aziz, Antonio ;

Onofrio, Robert C. ;

Parkin, Melissa ;

Pho, Nam H. ;

Quintanar-Jurado, Valeria ;

Ramos, Alex H. ;

Rebollar-Vega, Rosa ;

Rodriguez-Cuevas, Sergio ;

Romero-Cordoba, Sandra L. ;

Schumacher, Steven E. ;

Stransky, Nicolas ;

Thompson, Kristin M. ;

Uribe-Figueroa, Laura ;

Baselga, Jose ;

Beroukhim, Rameen ;

Polyak, Kornelia ;

Sgroi, Dennis C. ;

Richardson, Andrea L. ;

Jimenez-Sanchez, Gerardo ;

Lander, Eric S. ;

Gabriel, Stacey B. ;

Garraway, Levi A. ;

Golub, Todd R. ;

Melendez-Zajgla, Jorge ;

Toker, Alex ;

Getz, Gad ;

Hidalgo-Miranda, Alfredo ;

Meyerson, Matthew .

NATURE, 2012, 486 (7403) :405-409

[3] Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth [J].

Barbie, Thanh U. ;

Alexe, Gabriela ;

Aref, Amir R. ;

Li, Shunqiang ;

Zhu, Zehua ;

Zhang, Xiuli ;

Imamura, Yu ;

Thai, Tran C. ;

Huang, Ying ;

Bowden, Michaela ;

Herndon, John ;

Cohoon, Travis J. ;

Fleming, Timothy ;

Tamayo, Pablo ;

Mesirov, Jill P. ;

Ogino, Shuji ;

Wong, Kwok-Kin ;

Ellis, Matthew J. ;

Hahn, William C. ;

Barbie, David A. ;

Gillanders, William E. .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (12) :5411-5423

[4] High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients [J].

Bartholomeusz, Chandra ;

Gonzalez-Angulo, Ana M. ;

Liu, Ping ;

Hayashi, Naoki ;

Lluch, Ana ;

Ferrer-Lozano, Jaime ;

Hortobagyi, Gabriel N. .

ONCOLOGIST, 2012, 17 (06) :766-774

[5] Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer [J].

Baselga, Jose ;

Gomez, Patricia ;

Greil, Richard ;

Braga, Sofia ;

Climent, Miguel A. ;

Wardley, Andrew M. ;

Kaufman, Bella ;

Stemmer, Salomon M. ;

Pego, Antonio ;

Chan, Arlene ;

Goeminne, Jean-Charles ;

Graas, Marie-Pascale ;

Kennedy, M. John ;

Ciruelos Gil, Eva Maria ;

Schneeweiss, Andreas ;

Zubel, Angela ;

Groos, Jutta ;

Melezinkova, Helena ;

Awada, Ahmad .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) :2586-+

[6] Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research [J].

Bosch, Ana ;

Eroles, Pilar ;

Zaragoza, Rosa ;

Vina, Juan R. ;

Lluch, Ana .

CANCER TREATMENT REVIEWS, 2010, 36 (03) :206-215

[7] Androgen Receptor Expression Predicts Decreased Survival in Early Stage Triple-Negative Breast Cancer [J].

Choi, Jung Eun ;

Kang, Su Hwan ;

Lee, Soo Jung ;

Bae, Young Kyung .

ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (01) :82-89

[8] Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide [J].

Cochrane, Dawn R. ;

Bernales, Sebastian ;

Jacobsen, Britta M. ;

Cittelly, Diana M. ;

Howe, Erin N. ;

D'Amato, Nicholas C. ;

Spoelstra, Nicole S. ;

Edgerton, Susan M. ;

Jean, Annie ;

Guerrero, Javier ;

Gomez, Francisco ;

Medicherla, Satyanarayana ;

Alfaro, Ivan E. ;

McCullagh, Emma ;

Jedlicka, Paul ;

Torkko, Kathleen C. ;

Thor, Ann D. ;

Elias, Anthony D. ;

Protter, Andrew A. ;

Richer, Jennifer K. .

BREAST CANCER RESEARCH, 2014, 16 (01)

[9] Emerging targeted therapies in triple-negative breast cancer [J].

Crown, J. ;

O'Shaughnessy, J. ;

Gullo, G. .

ANNALS OF ONCOLOGY, 2012, 23 :56-65

[10] Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling [J].

Cuenca-Lopez, Maria D. ;

Montero, Juan C. ;

Morales, Jorge C. ;

Prat, Aleix ;

Pandiella, Atanasio ;

Ocana, Alberto .

BMC CANCER, 2014, 14

← 1 2 3 4 5 6 7 →